The impact of Mirabegron on sexual function in women with idiopathic overactive bladder

Marilena Gubbiotti¹,²*, Antonella Giannantoni³, Simona Cantaluppi⁴, Anna Chiara Coluccia⁴, Fabio Ghezzi⁴ and Maurizio Serati⁴

Abstract

Background: Overactive bladder (OAB) can frequently exert a negative effect on female sexual function. Mirabegron, a β3 receptor agonist, improves OAB symptoms, but there are very few information about its role on female sexual dysfunction (FSD). Aim of the study was to assess the impact of Mirabegron on FSD in women affected by OAB.

Methods: Fifty sexually active women suffering from idiopathic OAB were included in the study. Patients were assessed by means of a urogynecologic physical examination and were asked to complete the 3-day voiding diary, the International Consultation on Incontinence Questionnaire- Short Form (ICIQ-SF), the Female Sexual Function Index (FSFI) questionnaire and VAS, before and 12 weeks after treatment with Mirabegron. In addition, at the same time points, patients underwent uroflowmetry with the measurement of post-void residual volume (PVR).

Results: At baseline all patients were affected by OAB symptoms, with 49/50 patients (98%) presenting with FSD. At 12-weeks follow-up, OAB symptoms improved significantly in all patients, with 59.5% of subjects achieving a complete urinary continence. FSFI Total Score significantly improved in 42/50 patients (84%) from 18.9 ± 4.3 to 21.8 ± 4.5 (p < 0.0001). Sixteen cases (32%) presented with no FSD. Also mean ± SD scores of ICIQ-SF and VAS significantly improved (from 17.1 ± 5 to 7.9 ± 4.8 and from 3.9 ± 1.2 to 6.9 ± 1.2 respectively, p < 0.000).

Conclusions: Mirabegron not only is able to control urinary symptoms in women with OAB, but also induces a significant improvement in their sexual life.

Keywords: Mirabegron, Overactive bladder, Sexual dysfunction, Women

Brief summary

Women with OAB may suffer from sexual dysfunction. This study shows that Mirabegron is also able to improve female sexual function.

Prevalence of OAB has been reported to be 12.2% in women, becoming higher in patients aged > 40 years [2]. To date very few studies have investigated the impact of OAB symptoms on female sexual function [3, 4]. One of previous studies demonstrated a great deterioration in sexual Quality of Life (QoL) in women with OAB than in those with only urinary incontinence. In addition, it has been demonstrated that the improvement in OAB symptoms, as induced by a pharmacological treatment, can determine an amelioration also in female sexual life [5]. Mirabegron is a β3- agonist recently introduced in the treatment of OAB, with proven efficacy in reducing urgency and UUI, and with a good safety and tolerability profiles [6–8]. Moreover, Mirabegron has also been shown to exert a beneficial impact on health related QoL in treated patients [9]. Actually, there are no data

* Correspondence: marilena.gubbiotti@gmail.com

¹Department of Surgical and Biomedical Sciences, Uro-Oncology Section, University of Perugia, S. Maria della Misericordia Hospital, 06132 Perugia, Italy
²Istituto Serafico di Assisi, Centro di Ricerca “inVita”, 06081 Assisi, Perugia, Italy
³Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
on the impact of Mirabegron on sexual function in women affected by OAB. Aim of the study was to determine whether Mirabegron, used as a treatment for OAB symptoms, can have a positive effects also on Female Sexual Dysfunction (FSD) and to identify possible relationships between the improvement in urinary symptoms and changes in female sexual life.

Methods
This was an observational, analytical, prospective study performed in two Italian centers. The procedures were performed in accordance with the Declaration of Helsinki and approved by the local Ethics Committee (CEAS No. 12394/18). Patients gave their informed written consent to the study. Fifty sexually active women, with a confirmed diagnosis of idiopathic OAB, attending the Urogynecology outpatient clinic were consecutively enrolled. OAB was defined using the International Continence Society definition [10]: patients having urinary symptoms of urgency with or without UUI, with frequency and nocturia. All patients reported day-time urinary frequency of 8 or more times per day, urgency that may or may not accompanies UUI, urinary symptom’s duration of 3 months or longer. Subjects were excluded from participation if they had documented recurrent urinary tract infections (UTIs ≥ 3 episodes/year), urinary retention or clinically relevant Post-Void Residual volume (PRV), clinically significant voiding dysfunction (symptoms of hesitancy, slow streaming, intermittency, straining to void, feeling of incomplete bladder emptying), previous anti-incontinence or prolapse surgery, presence of a neurological cause of OAB, Pelvic Organ Prolapse Quantification (POQ ≥ stage II), any medical condition contraindicating the use of β3-agonist medications and previous pharmaceutical treatment or intradetrusor injections of botulinum toxin for OAB during the previous 3 months. Not sexually active women were also excluded from the study.

Screening visit
At the screening visit, patients underwent medical history, including a detailed sexual history, urogynecologic assessment (performed with the patient in the lithotomy position, and POP classified during a maximal Valsalva manoeuvre according to the POPQ system), blood pressure measurement, urinalysis and cultures, uroflowmetry with PVR, and VAS to score the impact of urinary symptoms on QoL (0 = worse; 10 = best). A 3- day voiding diary was used to record daily urgency and UUI episodes and day-time and night-time urinary frequencies. Patients underwent a validated Italian version of “International Consultation on Incontinence Questionnaire-Short Form” (ICIQ-SF) questionnaire. ICIQ-SF is a specific and brief questionnaire: it has four questions that rapidly assess the impact of UI and qualify the urinary losses of analysed patients in terms of frequency and severity, and eight self-diagnostic items related to causes or situations of UI experienced by patients. The questionnaire has a 0–10 numerical scale for assessment of the UI impact. Zero indicates little interference of UI in the interviewer’s daily life, and 10 represents a lot of interference. The total score is obtained by summing the questions related to frequency, quantity and impact on daily life, and can vary from 0 to 21 [11].

The assessment of sexual function and sexual QoL were performed by patient-reported questionnaires [12]. All patients were asked to complete the Female Sexual Function Index (FSFI) questionnaire, by using its validated Italian version [13]. FSFI is one of the most frequently adopted questionnaires in assessing female sexual function and dysfunction, and it has been strongly recommended from the latest report of International Consultation on Sexual Medicine. [14, 15] FSFI allows to study and classify the following domains: (a) desire (b) arousal (c) lubrication (d) orgasm (e) satisfaction and (f) pain. A total FSFI score of 26.5 is the cut-off to discriminate women with and without sexual dysfunction [16].

Treatment
All patients received a 12-week oral Mirabegron (50 mg once a day). We considered patients to be compliant only if they adhered to the therapy every day for 12 weeks.

Follow-up
At the 12-week follow-up examination, patients underwent blood pressure measurement, the 3-day voiding diary, uroflowmetry with PVR and ICIQ-SF and FSFI questionnaires and VAS.

Objective efficacy outcomes
Were: changes from baseline in the mean number of day-time and night-time urinary frequency, urgency and UUI; maximum flow rate at uroflowmetry with PVR.

Subjective efficacy outcomes
Were: changes from baseline in ICIQ-SF and FSFI scores and in VAS scores.

Side effect
Presence of side effects possibly related to the use of Mirabegron, such as hypertension, nasopharyngitis, and urinary tract infection was investigated. A daily blood pressure recording was performed during the first week of treatment and at the end of the study. Data were prospectively collected into a specifically designed digital database.
**Statistical analysis**
Statistical analysis was performed with IBM-SPSS v.17 for Windows (IBM Corp, Armonk, NY, USA). Student’s t test and the Mann–Whitney U test were performed to compare continuous parametric and nonparametric variables, as appropriate. Continuous variables were reported as median and Interquartile Range (IQR) or mean ± SD. Relationships between differences in FSFI and ICIQ-SF, urgency episodes, UUI, and frequency, were evaluated by Pearson coefficient analysis. A P value less than or equal to .05 was considered significant. Power calculation were done and we estimated that with 50 participants, the study would have 80% or greater power to detect a mean difference between the pre- and the post treatment FSFI total score of at least 3 points (considered clinically relevant), assuming a standard deviation of 2 and a two-sided type I error rate of 0.05.

**Results**
All the 50 patients completed the study. Mean ± SD age was 49.3 ± 11.3 years. All patients completed the questionnaires at the start of the study and at 12- week follow-up. Baseline characteristics of the study population are summarized in Table 1.

**Clinical results**
At initial evaluation (Table 2), all patients had increased day- time urinary frequencies and all complained of urgency. Forty- seven (94%) patients presented with UUI. At the 12- week follow- up, mean ± SD day- time and night- time urinary frequencies, daily urgency and UUI episodes decreased significantly (p < 0.0001). Twenty-eight/fifty (56%) patients achieved a complete urinary continence. On uroflowmetry, we did not observe any improvements in ICIQ-SF and FSFI scores after treatment (Table 3). At the 12- weeks follow-up, comparing changes in sexual function between the 28 continent patients and the remaining incontinent ones, FSFI domains significantly improved in those patients who obtained a complete urinary continence. (Table 4).

| Table 1 | Baseline characteristics of 50 women affected by idiopathic OAB with sexual dysfunction, treated with oral Mirabegron, 50 mg/day for 12 weeks |
|---------|--------------------------------------------------------------------------------------------------|
| **N = 50** |
| Age (years) | 50 (36–60) |
| BMI (kg/m²) | 23.3 (23–28) |
| Obese (BMI ≥ 30) | 5 (10%) |
| Menopausal | 19 (38%) |
| Previous vaginal deliveries | 1 (1–2) |
| Macrosome (≥4000 g) | 10 (20%) |
| Operative delivery (vacuum/forceps) | 5 (10%) |

Data are expressed as absolute number (%) or median (IQR)

**Table 2** Urinary symptoms and uroflowmetry results in 50 women affected by idiopathic OAB and sexual dysfunction before and after treatment with oral Mirabegron, 50 mg/day

| Urinary symptoms and uroflowmetry results | Baseline (mean ± SD) | 12 weeks follow-up (mean ± SD) | p value |
|------------------------------------------|----------------------|-----------------------------|---------|
| Day-time urinary frequency/day | 10.1 ± 2.2 | 6 ± 1.1 | <0.0001 |
| Night-time urinary frequency/day | 1.6 ± 1.2 | 0.7 ± 0.8 | 0.0001 |
| Daily urgency episodes | 5.2 ± 2.3 | 2.3 ± 1.8 | <0.0001 |
| Urge urinary incontinence frequency/day | 2.1 ± 1.3 | 0.7 ± 0.9 | <0.0001 |
| Qmax(ml/sec) | 25.1 ± 8.3 | 25.2 ± 7.9 | 0.83 |
| Post-void residual volume(ml) | 5.8 ± 9.5 | 3 ± 5.8 | 0.32 |

**Sexual function and sexual QoL**
At initial evaluation, 49/50 patients (98%) presented with FSD (FSFI Total Score < 26.55). At 12- weeks follow- up, 42/50 patients (84%) reported improvements in the FSFI Total Score and 16 patients (32%) had no FSD (Table 3). Mean ± SD FSFI Total Score significantly increased from 18.9 ± 4.3 to 21.9 ± 4.5 (p < 0.0001). The domains most relevantly impaired were arousal and lubrication, orgasm and pain. After treatment with Mirabegron, an improvement was noted in all the domains but pain remained unchanged (Table 3). At the 12- weeks follow-up, when comparing changes in sexual function between the 28 continent patients and the remaining incontinent ones, FSFI domains significantly improved in those patients who obtained a complete urinary continence. (Table 4).

We found a significant relationship between improvements in ICIQ-SF and FSFI scores after treatment (r = 0.5; p = 0.007). Moreover, we could detect a significant relationship between the reduction in daily urgency episodes and the improvement in FSFI score (r = 0.45; p = 0.03). On the contrary, the relationship between daily UUI episodes, urinary frequency and FSFI total score was not statistically significant (r = -0.1; p = 0.35).

**Table 3** FSFI scores in 50 patients affected by idiopathic OAB symptoms and sexual dysfunction, before and 12 weeks after treatment with oral Mirabegron, 50 mg/day

| FSFI domains | Baseline (mean ± SD) | 12-weeks follow-up (mean ± SD) | p value |
|--------------|----------------------|-----------------------------|---------|
| Desire | 3.03 ± 0.65 | 3.51 ± 0.88 | 0.04 |
| Arousal | 2.87 ± 0.61 | 3.35 ± 0.94 | <0.0001 |
| Lubrication | 3.31 ± 0.72 | 3.93 ± 1.06 | 0.0008 |
| Orgasm | 3.36 ± 0.74 | 3.80 ± 0.96 | 0.0001 |
| Satisfaction | 3.33 ± 0.91 | 4.04 ± 1.05 | 0.0008 |
| Pain | 3.24 ± 0.88 | 3.52 ± 0.93 | 0.58 |
| Total FSFI score | 18.9 ± 4.3 | 21.9 ± 4.5 | <0.0001 |
Table 4. FSFI scores in 50 women affected by idiopathic OAB symptoms and sexual dysfunction, before and 12 weeks after treatment with oral Mirabegron, 50 mg/day

| Patients (No.) | FSFI Total Score baseline (mean ± SD) | FSFI Total Score 12-weeks f-up (mean ± SD) |
|---------------|--------------------------------------|------------------------------------------|
| Continent (28) | 22 ± 3.7                             | 27.5 ± 3.5                               |
| Incontinent (22) | 14.1 ± 3.1                           | 21 ± 3.2                                 |

Comparison between continent and incontinent patients before and after treatment with Mirabegron

Side effects
None of the patients reported any increase in systolic and/or diastolic pressure along the whole follow-up. At the 12-week follow-up, 2 patients presented with UTIs.

Discussion
This study seems to show that the treatment of OAB with Mirabegron 50 mg per day for 12 weeks is able to improve sexual function in female patients with OAB.

In the last years, an enormous interest has emerged in sexual life of patients affected by OAB. Nevertheless, there is still limited knowledge about the impact of OAB therapies on sexual function.

This study was addressed to evaluate whether treatment with the β3- agonist Mirabegron and a corresponding improvement in OAB symptoms could be associated with an amelioration on FSD. Herein we demonstrate for the first time that Mirabegron, given to control OAB in women, was able not only to improve urinary symptoms but also many aspects of sexual life of these patients in the short-term follow-up.

Specifically, we found that all OAB symptoms and ICIQ-SF total score significantly improved at the 12-week follow-up. At the same time point, a significant amelioration was found also in sexual dysfunction, as assessed by the FSFI questionnaire. In addition, the impact of urinary symptoms on QoL, as assessed by VAS, also showed a significant reduction. Worth of noting, ameliorations in urinary urgency and in ICIQ-SF scores were significantly related to the improvement in FSFI scores, with desire, arousal, satisfaction, lubrication and orgasm being the most improved domains.

Indeed, at baseline, our patients presented with FSFI scores (mean ± SD: 18.9 ± 4.3) lower than that reported in the accepted definition of FSD (FSFI ≤26.5), with arousal, lubrication, orgasm-related problems and pain most relevantly impaired. Twelve weeks after treatment with Mirabegron, FSFI total score significantly improved, particularly in those patients who achieved a complete urinary continence, although patients still presented with low FSFI values (mean ± SD: 21.9 ± 4.5), which did not reach the suggested cut-off. In the literature, the cut-off point in the FSFI score to define clinical improvement is unclear and FSFI is adopted as an assessment tool to determine any change post-treatment.

Few data exist in the literature regarding the effect of OAB treatments on female sexual function. Sand et al. demonstrated that women treated with transdermal oxybutynin reported improvements in sexual function at 6 months [17]. In the study of Hajebramhi et al., 30 sexually active OAB women underwent treatment with tolterodine immediate release in order to control their OAB symptoms. In these patients, significant improvements have been reported not only in urinary symptoms but also in the mean ASEX score at all the considered follow-up time points [18]. In a randomized, placebo-controlled study, Rogers and co-workers observed a significant amelioration in urinary symptoms and sexual dysfunction in female patients treated with tolterodine extended-release, as compared to those treated with placebo, at 3 months follow up [19]. Finally, significant improvements in total FSFI score and in OAB symptoms have been observed also in patients undergoing sacral neuromodulation or onabotulinumtoxin A intradetrusor injections [5, 20]. Although Mirabegron has been demonstrated to be effective and safe in the treatment of OAB in naïve patients or in those refractory to anticholinergics [21], to date data related to an eventual effect on sexual dysfunction are completely lacking. The results in our study may be in favour of a causal relationship between urinary symptoms and sexual dysfunction in women [22]. Since Mirabegron induced improvements in all OAB symptoms and a complete urinary continence in a large proportion of patients, we retain that the positive effect on sexual dysfunction could be attributed to an indirect effect by the urologic clinical and QoL amelioration. Overall, Mirabegron was well tolerated without any systemic side effects along the whole follow-up and it did not affect the bladder emptying, as already demonstrated in the literature.

Possible limitations of the present study are the short-term follow-up and the lack of a control or a placebo group. Indeed, no patient was lost to follow-up, and the limited improvement in sexual function observed in patients not reaching a complete urinary continence can strengthen these results.

Conclusion
This study could advance the understanding of FSD in women with OAB and the possibility of intervening with new pharmacologic oral agents in the treatment of OAB. In our study the improvement in sexual dysfunction observed in patients treated with Mirabegron can be explained by the amelioration in OAB symptoms and in urinary incontinence. However, future trials with a larger patient population should confirm these preliminary findings. In conclusion, according to our research,
treatment of OAB with Mirabegron 50 mg per day for 12 weeks is able to improve sexual function in women affected by OAB. This finding can improve our counseling when we prescribe this pharmacological therapy of OAB.

Abbreviations
BMI: Body Mass Index; FSD: Female Sexual Dysfunction; FSFI: Female Sexual Function Index; ICQ-SF: International Consultation on Incontinence Questionnaire-Short Form; IQR: Interquartile Range; OAB: Overactive Bladder; POP(Q): Pelvic Organ Prolapse (Quantification); PVR: Post- Void Residual volume; Qmax: Maximum Flow rate; QoL: Quality of Life; SD: Standard Deviation; UTIs: Urinary Tract Infections; UUI: Urge Urinary Incontinence

Acknowledgements
None.

Funding
No funding was obtained for this study.

Availability of data and materials
The data of the current study are available from the corresponding author on reasonable request.

Authors’ contributions
MG, AG and MS contributed to conception and design, collected data, contributed to the analysis and interpretation of data, drafted the manuscript and revised it critically for important intellectual content. SC, ACC analyzed and contributed to the analysis and interpretation of data, drafted the manuscript and revised it critically for important intellectual content. FG contributed to conception, design of data. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by the local Ethics Committee (CEAS Umbria, CEAS No. 12394/18). Written informed consent was obtained from all study participants prior to commencement of the study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Surgical and Biomedical Sciences, Uro- Oncology Section, University of Perugia, S. Maria della Misericordia Hospital, 06132 Perugia, Italy. 2Istituto Serafico di Assisi, Centro di Ricerca “InVita”, 06081 Assisi, Perugia, Italy. 3Department of Medical and Surgical Sciences and Neuroscience, Urology Section, University of Siena, Siena 53100, Italy. 4Department of Obstetrics and Gynecology, University of Insubria, Varese 21100, Italy.

Received: 3 August 2018 Accepted: 14 January 2019 Published online: 21 January 2019

References
1. International Continence Society. First report on the standardization of terminology of lower urinary tract function. Br J Urol. 1976;48:39.
2. Irwin DE, Milsom I, Hunskaar S, et al. Population- based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306.
3. Patel AS, O’Leary ML, et al. The relationship between overactive bladder and sexual activity in women. Int Braz J Urol. 2006;32:77.
4. Rogers RG, Bachmann G, Jumadilova Z, et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:1551.
5. Giannantoni A, Piroetti S, Giusti G, et al. OnabotulinumtoxinA intradetrusor injections improve sexual function in female patients affected by multiple sclerosis: preliminary results. World J Urol. 2015;33:2095.
6. Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63:296.
7. Khullar V, Amaneco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63:283.
8. Tubaro A, Batista JE, Nitti VW, et al. Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies. Ther Adv Urol. 2017;9:137.
9. Freeman R, Foley S, Rosa Arias J, et al. Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study. Curr Med Res Opin. 2017;18:1.
10. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the international continence society. Urology. 2003;61:37.
11. Tubaro A, Zattoni F, Prezioso D, et al. Flow study group. Italian validation of the international consultation on incontinence questionnaires. BJU Int. 2006;97:101.
12. Hatzichristou D, Rosen RC, Broderick G, et al. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med. 2004;1:49.
13. Filocamo MT, Serati M, Li Marzi V, et al. The female sexual function index (FSFI): linguistic validation of the Italian version. J Sex Med. 2014;11:447.
14. Hatzichristou D, Kirana PS, Banner L, et al. Diagnosing sexual dysfunction in men and women: sexual history taking and the role of symptom scales and questionnaires. J Sex Med. 2016;13:1166.
15. Zachriou A, Filippini M. The effect of extended release tolterodine used for overactive bladder treatment on female sexual function. Int Braz J Urol. 2017;43:713.
16. Wiegł M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31:1.
17. Sand PK, Goldberg RP, Dmochowski RR, et al. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the multicenter assessment of transdermal therapy in overactive bladder with oxybutynin trial. Am J Obstet Gynecol. 2006;195:1730.
18. Hajebrahimi S, Azaripour A, Sadeghi- Bazargani H. Tolterodine immediate release improves sexual function in women with overactive bladder. J Sex Med. 2008;5:2880.
19. Rogers RG, Bachmann G, Scarpero H, et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Curr Med Res Opin. 2009;25:2159.
20. Signorello D, Seitz CC, Berner L, et al. Impact of social neuromodulation on female sexual function and its correlation with clinical outcome and quality of life indexes: a monocentric experience. J Sex Med. 2011;8:1147.
21. Serati M, Leone Roberto Maggiore U, Sorice P, et al. Publication Committee of the Italian Society of Urodynamics. Is mirabegron equally as effective when used as first- or second-line therapy in women with overactive bladder? Int Urogynecol J. 2017;28:1039.
22. Juliano CRT, Melotti I, Li, Junior LCS, et al. Does the severity of overactive bladder symptoms correlate with risk for female sexual dysfunction? J Sex Med. 2017;14:904.